Table 1 Overview of included studies of Dacron® vs. PTFE as bypass materials in peripheral vascular surgery
Author | Year | Indication | Site of bypass | Intervention | Additional intervention | Follow-up (years) | N* | Primary patency (N = number of patients or grafts under risk) | Superior primary patency | Funding | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Baseline | End of study | ||||||||||
Johnson and Lee [12] | 1999 | disabling claudication, rest pain or tissue necrosis | femorofemoral, axillofemoral, axillobifemoral | Dacron® vs. PTFE | Aspirin 650 mg/d | 5 | 419 | 47 | At 1, 3, 5 years: - Dacron®: 79%, 63%, 50% (N = 125, 73, 32) - PTFE: 77%, 62%, 47% (N = 103, 53, 15) | n.s. (p-value not reported) | n.r. |
Robinson et al. [13] | 1999 | disabling claudication, rest pain or tissue necrosis | femoropopliteal (above-knee and below-knee) | gelatine-sealed Dacron® vs. PTFE | Cephalothin, Heparin, Aspirin | 3 | 108 | 19 | At 1, 2, 3 years: - Dacron®: 70%, 56%, 47% (N = 27, 18, 9) - PTFE: 72%, 52%, 52% (N = 33, 16, 10) | n.s. (p = 0.87) | n.r. |
Green et al. [14] | 2000 | superficial femoral artery occlusion | femoropopliteal (above-knee) | collagen-impregnated Dacron® vs. ePTFE | n.r. | 5 | 240 | 10 | At 1, 3, 5 years:: - Dacron®: 78%, 65%, 45% (N = 65, 25, 5) - PTFE: 80%, 63%, 43% (N = 66, 21, 5) | n.s. (p-value not reported) | manufacturer of Dacron® |
Post et al. [15] | 2001 | indication for artificial graft of at least 20 cm length | femoropopliteal (above-knee and below-knee) | unsealed Dacron® vs. PTFE | Anti-platelet drugs, Heparin or Coumadin | 3 | 194 | 50 | At 3 years (N = grafts under risk): - Dacron®: 64% (95%-CI [55%;74%], N = 28) - PTFE: 61% (95%-CI [49%;72%], N = 22) | n.s. (p = 0.89) | manufacturer of Dacron® and PTFE |
Prager et al. [16] | 2003 | aortoiliac occlusive disease | aortoiliac | gelatine-coated Dacron® vs. collagen-coated Dacron® vs. PTFE | Antibiotics, Heparin 70 IU/kg, Fraxiparine 100 mg/kg/d (bid for patients with anastomoses) | 8 | 149 | 35 | At 5, 8 years: - C-Dacron®: 89%, 78% (N = 24, 11) - G-Dacron®: 92%, 77% (N = 26, 11) - PTFE: 88%, 79% (N = 29, 13) | n.s. (p > 0.8) | n.r. |
Robinson and Fletcher [17] | 2003 | disabling claudication, rest pain or tissue loss | femoropopliteal (above-knee and below-knee) | fluoropolymer-coated Dacron® vs. PTFE | Cephalothin, Heparin, Aspirin | 2 | 129 | 21 | At 6, 12, 24 month: - Dacron®: 50%, 36%, 36% (N = 27, 17, 9) - PTFE: 71%, 56%, 47% (N = 43, 28, 12) | PTFE (p = 0.002) | manufacturer of Dacron® and PTFE |
Devine and McCollum [18] | 2004 | occlusive arterial disease (superficial femoral or popliteal artery) | femoropopliteal (above-knee and below-knee) | collagen-coated, heparin-bonded Dacron® vs. PTFE | Aspirin 300 mg/d | 5 | 209 | 45 | At 1, 3, 5 years: - Dacron®: 71%, 54%, 46% (N = 70, 45, 20) - PTFE: 62%, 44%, 35% (N = 62, 42, 25) | n.s. (p = 0.05) | n.r. |
Eiberg et al. [19] | 2006 | uni-ilia occlusive disease | femorofemoral | fluoropassivated, gelatine-sealed Dacron® vs. ePTFE | n.r. | 2 | 198 | 136 | At 1, 2 years: - PTFE: 94%, 93% (N = 74, 63) - Dacron®: 92%, 87% (N = 87, 73) | n.s. (p = 0.350) | manufacturer of Dacron® and PTFE |
Jensen et al. [20] | 2007 | chronic lower limb ischaemia | femoropopliteal (above-knee) | gelatine-coated Dacron® vs. PTFE | n.r. | 2 | 413 | 150 | At 2 years: - Dacron®: 70% (N = 78) - PTFE: 57% (N = 72) | Dacron® (p = 0.002) | manufacturer of Dacron® |